Fridge-free vaccines tested in Africa, breakthrough for cold-chain waste

Vaccine waste has long been a critical barrier to immunization in low-income regions, particularly Africa. The article identifies that around half of all vaccines are wasted annually, with much of that loss stemming from breaks in the "cold chain"—the requirement to maintain precise temperatures from manufacturing through patient injection. In Africa specifically, one in five children remain unvaccinated, a gap that reflects not just access to vaccines themselves but the infrastructure cost of maintaining cold storage across supply chains that span vast distances with limited electricity. Stablepharma's trehalose-powder approach directly addresses this bottleneck by eliminating the need for refrigeration altogether, moving the temperature-stability problem from logistics to chemistry. The successful first-in-patient trial is significant because it proves the concept works in real conditions, not merely in the laboratory. The coming larger trial represents the final regulatory and safety validation step before potential rollout, suggesting the path to deployment is now concrete rather than theoretical.